The Wayback Machine - https://web.archive.org/all/20041013040503/http://www.chemscope.com:80/news.asp?name=2147

CSI Store
Browse Our Store
Your Basket
Your Profile
Track Orders
Log-out

CSI News
CSI HOME
Administration
BioFunnies
Classifieds
Conferences
FDA Approvals
FDA Sites
FDA Warnings
Medical Summary
New Products
News Archives
Newswire Post
News Summary
Online Discuss
Position Open
Position Sought
Stock Quotes
Suppliers

CSI Services
Price List
Advertising
Colocation
Consulting
Hosting
News Dlvr
Online Store
Personal
Professional
Supplier Order

CSI Suppliers
Adhesives
Antibodies
Biological
Biologicals
Biotech
Catalogues
Cells
Chemicals
Chemistry
Chromatography
Clean Room
Components
Contract Manuf.
Converters
Design
Devices
DNA
Elastomers
Electrical
Electronics
Engineering
Equipment
Excipients
Filters
Furniture
Gas
Hardware
Institutes
Instrumentation
Kits
Lab Materials
Labels
Laboratory
Manufacturing
Materials
Media
Motion Control
Motors
Optical
Organizations
Packaging
Pharmaceutics
Printing
Product Design
Production
Pumps
Services
Software
Sterilization
Testing
Toxicological
Tubing
Valves

Search Engines
Starting Point
ClearingHouse
Four11
Galaxy
Global
Point
Magellan
Pointers
Web Voyager
Yahoo
Yellow Pages
Alta Vista
Excite
HotBot
NetCenter
Lycos
Nikos
OpenText
WebCrawl 
InfoSeek

Electronic Commerce  egmp.com - cGMP document control cGMP Documents 
ChemScope

FDA ADVISORY COMMITTEE TO REVIEW NATRECOR NEW DRUG APPLICATION

SCIOS ANNOUNCES FDA CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE TO
REVIEW NATRECOR NEW DRUG APPLICATION

SUNNYVALE, CA, April 10, 2001 - Scios Inc. (Nasdaq: SCIO) announced today
that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs
Advisory Committee will review the company's New Drug Application (NDA)
amendment for Natrecor (nesitritide) for the treatment of acute congestive
heart failure (CHF) on Friday, May 25, 2001.

Scios submitted an amendment to its existing NDA for Natrecor at the
beginning of this year, based largely on the findings of the 498-patient
VMAC (Vasodilation in the Management of Acute Congestive heart failure)
trial. If approved, Natrecor would be the first new treatment for acute CHF
in more than a decade.

"We are pleased to have the opportunity to present all of the Natrecor data,
particularly the VMAC data, to the FDA Advisory Committee," said Darlene P.
Horton, M.D., Scios' Vice President of Medical Affairs. "We have been
working closely with the Agency and believe we can present a compelling case
regarding the approvability of this drug."

In addition to Dr. Horton from Scios, James B. Young, M.D., Chair, VMAC
Steering Committee and Head, Section of Heart Failure and Cardiac Transplant
Medicine and Medical Director of the Kaufman Center for Heart Failure at the
Cleveland Clinic Foundation and William Abraham, M.D., Chief, Division of
Cardiovascular Medicine and Director, Section of Heart Failure and Cardiac
Transplantation, University of Kentucky College of Medicine, will present
Natrecor data.

"The Advisory Committee review of the data supporting the application for
approval of Natrecor is an important step for Natrecor and an important
event for other applications to follow for this indication," commented
Richard B. Brewer, Scios' Chief Executive Officer. "As we have indicated
previously, we have been expecting and preparing for Advisory Committee
review."

Natrecor is a recombinant form of B-type natriuretic peptide (BNP), a
naturally occurring hormone in the body that aids healthy functioning of the
heart. It causes arteries and veins to dilate, alleviating symptoms by
improving blood movement around the heart without a change in heart rate.
Natrecor is administered intravenously, primarily in a standard fixed dose
regimen that not require titration (i.e., dose adjustments). Roughly five
million Americans suffer from heart failure, and there are approximately one
million hospitalizations each year in the United States for acute heart
failure.

Immediately following the Advisory Committee meeting, Scios will host a
conference call and webcast to discuss the results of the meeting. The
webcast and conference call will begin at 6:00 pm (ET) on Friday, May 25th.
The webcast will be available on Scios' website, www.sciosinc.com. The
conference call dial-in will be (800) 314-7867. A replay of both the
conference call and webcast will be available through June 1, 2001. The
replay dial-in number will be (888) 203-1112, confirmation code 593777.

Scios Inc.
Scios is a biopharmaceutical company developing novel treatments for heart
failure and rheumatoid arthritis. The company's disease-based technology
platform integrates expertise in protein biology with combinatorial and
medicinal chemistry to identify novel targets and rationally design large
and small-molecule compounds to treat cardiovascular and inflammatory
diseases, two of the world's leading unmet medical needs. Additional
information on Scios is available at its web site located at
www.sciosinc.com and in the company's various filings with the Securities
and Exchange Commission.

The statements in this press release that are not historical facts are
forward-looking statements that involve risks and uncertainties. These
include uncertainties associated with anticipating the response of the FDA
and the Advisory Committee to the results of the VMAC trial, the timing of
regulatory approval of Natrecor, and acceptance by the medical community of
Natrecor as a new therapy for acute decompensated CHF, as well as other
risks detailed from time to time in the reports filed by Scios with the SEC,
including the company's annual report on form 10-K for the year ended
December 31, 2000.

Please click here for more information..

Biotech., Pharm., and Med. Device News

Biotechnology News - Summary

Post Comments to Discussion Board

(Please fill in ALL fields)
Author:
Message:

Supplier / Biopharmaceutical Search Directory
To purchase life science products online, please Visit our Store. For existing orders, please Track Orders. To find and contact life science product suppliers, please go below to search by supplier, product name, or product category, or browse supplier class or name.

Search by Supplier   Search by Product   Search by Product Category

Supplier Browse by Name
A  B  C  D  E  F  G  H  I  J  K  L  M  N 
O  P  Q  R  S  T  U  V  W  X  Y  Z 

Supplier Site Administration    Create New Supplier

The ChemScope Corporation
PO Box 391143, Mountain View, CA 94041
(415) 531-6319 (650) 903-1681 (fax) info@chemscope.com
Copyright © 1995-2001 All Rights Reserved